GET DAILY SIGNALSEthos Technologies (LIFE) Reports Strong Q3 with 151% Revenue Growth
Key Takeaways
- Ethos Technologies reported third-quarter fiscal 2026 revenue of $235.2 million, up 151% year over year and well above the consensus estimate of $169.0 million.
- Non-GAAP earnings per share (EPS) came in at $0.49, beating the consensus estimate of $0.35.
- Adjusted EBITDA reached $35 million, up 87% year over year with a 15% margin.
- Both sales channels posted triple-digit growth, with the direct channel up 112% and the third-party channel up 209%.
- Management raised its full-year 2026 outlook, now guiding revenue to a range of $838 million to $842 million.
- The company activated 142,111 insurance policies during the quarter, with average revenue per policy of $1,655.
Earnings Context and Its Significance
Ethos Technologies is a life insurance technology company that went public in January 2026. It operates as a platform linking consumers, agents, and insurance carriers. As a relatively new public company, every quarterly update provides an early signal on whether its fast-paced growth can hold up amid ongoing investments in products and distribution channels.
For investors, this quarter stands out for two main reasons. It tests whether the triple-digit revenue expansion seen earlier in 2026 can persist. It also shows whether rising sales are translating into better profitability and cash flow. Analysts had modeled roughly $169 million in revenue ahead of the report, so the actual results offered a clear test of demand in both the direct-to-consumer and third-party agency channels.
Quarterly Performance Details
For the third quarter of fiscal 2026 ended September 30, 2026, LIFE posted total revenue of $235.2 million, a 151% increase from $93.8 million a year earlier and comfortably above the $169.0 million consensus. Non-GAAP EPS of $0.49 exceeded the $0.35 estimate.
Direct channel revenue rose 112% year over year to $119 million, while third-party channel revenue climbed 209% to $116 million. Adjusted EBITDA increased 87% to $35 million, producing a 15% margin. Contribution profit grew 81% to $66 million, for a 28% contribution margin.
Management lifted its outlook. For the fourth quarter, the company now expects revenue between $220 million and $224 million and adjusted EBITDA of $30 million to $32 million. For the full year 2026, it projects revenue of $838 million to $842 million and adjusted EBITDA of $134 million to $136 million.
Market Response After the Release
Ethos Technologies released results after the close on November 2, 2026. Shares finished the regular session at $42.62, down 1.77% for the day, then climbed more than 9% in after-hours trading as investors reacted to the revenue beat and the higher full-year guidance.
The move higher highlights focus on the company’s accelerating growth and its ability to top estimates on both the top and bottom lines. The raised outlook for the rest of fiscal 2026 added confidence that the momentum is sustainable. At the same time, the stock is still young and can remain volatile, with sentiment sensitive to guidance details and execution in the expanding third-party channel.
Looking Ahead: Factors Worth Tracking
Investors will monitor a few key items to gauge whether Ethos Technologies can keep its growth path intact. The most immediate is the fourth-quarter revenue range of $220 million to $224 million, which points to roughly 102% year-over-year growth at the midpoint. Delivering on that would extend the streak of triple-digit expansion.
Profitability trends also deserve attention. While adjusted EBITDA is improving, contribution margins will need watching as the faster-growing third-party channel takes on a bigger role. Management has indicated that this channel has a different cash conversion profile, so the revenue mix will affect both margins and near-term cash flow.
Additional items to follow include policy activation volumes, average revenue per policy, and the balance of accounts and commissions receivable, which management sees as a forward indicator of cash generation. Broader industry conditions, such as consumer demand for life insurance and competition from established carriers, could also play a role. Execution will ultimately determine outcomes, and investors should balance the company’s growth investments against its route to sustained profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Exploring AI Tools for Stock Analysis
In my own research process, I often turn to Tickeron’s AI Screener when evaluating names like this one. It lets me apply customizable filters across technical patterns, fundamentals, and performance metrics to quickly surface comparable ideas or confirm trends. The tool has become a regular part of my workflow for identifying potential opportunities without spending hours on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LIFE in -2.83% downward trend, declining for three consecutive days on October 26, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where LIFE declined for three days, in 182 of 214 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for LIFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 19 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
LIFE broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on LIFE as a result. In 38 of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for LIFE just turned positive on October 12, 2026. Looking at past instances where LIFE's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.
LIFE moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LIFE crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +2.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where LIFE advanced for three days, in 132 of 170 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 84 of 98 cases where LIFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. LIFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.707) is normal, around the industry mean (2.659). LIFE has a moderately low P/E Ratio (-25.534) as compared to the industry average of (18.304). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.322). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (4.186) is also within normal values, averaging (2.968).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of protein therapeutics and novel class of biologic drugs
Industry InsuranceBrokersServices
Advertisement